BACKGROUND: The objectives of this study were to assess the impact among young men of herpes simplex virus type 2 (HSV-2) status on the acquisition of human immunodeficiency virus (HIV) and on the protective effect of male circumcision against HIV acquisition. METHODS: We used data collected during a male circumcision trial conducted in Orange Farm, South Africa. We estimated adjusted incidence rate ratios (IRRs) for HIV acquisition, using survival analysis and background characteristics, HSV-2 status, male circumcision status, and sexual behavior as covariates. RESULTS: Compared with subjects who remained HSV-2 negative throughout the study, subjects who were HSV-2 positive at enrollment had an adjusted IRR of 3.3 (95% confidence interval [CI], 1.5-7.4; P=.004), and those who became HSV-2 positive during follow-up had an adjusted IRR of 7.0 (95% CI, 3.9-12.4; P<.001). The population fraction of incident HIV infection attributable to HSV-2 was 27.8% (95% CI, 17.7%-37.2%). Intention-to-treat analysis of the protective effect of male circumcision on HIV acquisition was the same among men with and men without HSV-2 (0.38 vs. 0.37; P=.93). CONCLUSIONS: This study shows that HSV-2 has a substantial impact on HIV acquisition among young South African men. It suggests that HSV-2 infection enhances HIV acquisition and is responsible for approximately 25% of incident cases of HIV infection. However, the protective effect of male circumcision against HIV acquisition appears independent of HSV-2 serostatus. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00122525.
RCT Entities:
BACKGROUND: The objectives of this study were to assess the impact among young men of herpes simplex virus type 2 (HSV-2) status on the acquisition of human immunodeficiency virus (HIV) and on the protective effect of male circumcision against HIV acquisition. METHODS: We used data collected during a male circumcision trial conducted in Orange Farm, South Africa. We estimated adjusted incidence rate ratios (IRRs) for HIV acquisition, using survival analysis and background characteristics, HSV-2 status, male circumcision status, and sexual behavior as covariates. RESULTS: Compared with subjects who remained HSV-2 negative throughout the study, subjects who were HSV-2 positive at enrollment had an adjusted IRR of 3.3 (95% confidence interval [CI], 1.5-7.4; P=.004), and those who became HSV-2 positive during follow-up had an adjusted IRR of 7.0 (95% CI, 3.9-12.4; P<.001). The population fraction of incident HIV infection attributable to HSV-2 was 27.8% (95% CI, 17.7%-37.2%). Intention-to-treat analysis of the protective effect of male circumcision on HIV acquisition was the same among men with and men without HSV-2 (0.38 vs. 0.37; P=.93). CONCLUSIONS: This study shows that HSV-2 has a substantial impact on HIV acquisition among young South African men. It suggests that HSV-2 infection enhances HIV acquisition and is responsible for approximately 25% of incident cases of HIV infection. However, the protective effect of male circumcision against HIV acquisition appears independent of HSV-2 serostatus. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00122525.
Authors: H A Weiss; A Buvé; N J Robinson; E Van Dyck; M Kahindo; S Anagonou; R Musonda; L Zekeng; L Morison; M Caraël; M Laga; R J Hayes Journal: AIDS Date: 2001-08 Impact factor: 4.177
Authors: B Auvert; R Ballard; C Campbell; M Caraël; M Carton; G Fehler; E Gouws; C MacPhail; D Taljaard; J Van Dam; B Williams Journal: AIDS Date: 2001-05-04 Impact factor: 4.177
Authors: María del Mar Pujades Rodríguez; Angela Obasi; Frank Mosha; Jim Todd; David Brown; John Changalucha; David Mabey; David Ross; Heiner Grosskurth; Richard Hayes Journal: AIDS Date: 2002-02-15 Impact factor: 4.177
Authors: Steven J Reynolds; Arun R Risbud; Mary E Shepherd; Jonathan M Zenilman; Ronald S Brookmeyer; Ramesh S Paranjape; Anand D Divekar; Raman R Gangakhedkar; Manisha V Ghate; Robert C Bollinger; Sanjay M Mehendale Journal: J Infect Dis Date: 2003-04-23 Impact factor: 5.226
Authors: Aaron A R Tobian; Godfrey Kigozi; Andrew D Redd; David Serwadda; Xiangrong Kong; Amy Oliver; Fred Nalugoda; Thomas C Quinn; Ronald H Gray; Maria J Wawer Journal: J Infect Dis Date: 2011-12-05 Impact factor: 5.226
Authors: Aaron A R Tobian; Godfrey Kigozi; Maria J Wawer; David Serwadda; Thomas C Quinn; Ronald H Gray Journal: AIDS Date: 2013-01-02 Impact factor: 4.177
Authors: Christophe Vanpouille; Andrea Lisco; Marco Derudas; Elisa Saba; Jean-Charles Grivel; Beda Brichacek; Francesca Scrimieri; Raymond Schinazi; Dominique Schols; Christopher McGuigan; Jan Balzarini; Leonid Margolis Journal: J Infect Dis Date: 2010-02-15 Impact factor: 5.226
Authors: Ronald H Gray; David Serwadda; Aaron A R Tobian; Michael Z Chen; Frederick Makumbi; Tara Suntoke; Godfrey Kigozi; Fred Nalugoda; Boaz Iga; Thomas C Quinn; Lawrence H Moulton; Oliver Laeyendecker; Steven J Reynolds; Xiangrong Kong; Maria J Wawer Journal: PLoS Med Date: 2009-11-24 Impact factor: 11.069
Authors: Stephanie L Sansom; Vimalanand S Prabhu; Angela B Hutchinson; Qian An; H Irene Hall; Ram K Shrestha; Arielle Lasry; Allan W Taylor Journal: PLoS One Date: 2010-01-18 Impact factor: 3.240